GatePass Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WisdomTree Floating Rate Treasury Fund
USFR
|
+$2.98M |
| 2 |
JPMorgan Ultra-Short Income ETF
JPST
|
+$1.03M |
| 3 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$829K |
| 4 |
Evolv Technologies
EVLV
|
+$694K |
| 5 |
Janus Henderson AAA CLO ETF
JAAA
|
+$656K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
INmune Bio
INMB
|
+$1.84M |
| 2 |
GraniteShares ETF Trust GraniteShares 2x Long NVDA Daily ETF
NVDL
|
+$672K |
| 3 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$469K |
| 4 |
Vanguard Short-Term Treasury ETF
VGSH
|
+$439K |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$407K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 18.65% |
| 2 | Consumer Discretionary | 5.74% |
| 3 | Technology | 5.27% |
| 4 | Industrials | 3.33% |
| 5 | Consumer Staples | 2.14% |
Similar funds
GatePass Capital's Q2 2025 Portfolio in Review
As of Q2 2025, GatePass Capital held 131 positions worth $151M, up 13% from $134M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
GatePass Capital deployed $5.25M of net new capital in Q2 2025, opening 17 new positions and adding to 41 existing holdings. Its largest new stake was iShares Broad USD High Yield Corporate Bond ETF: 22,600 shares worth $848K.
By sector, the portfolio is most concentrated in Financials at 19% of assets, down from 19% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was GraniteShares ETF Trust GraniteShares 2x Long NVDA Daily ETF, an estimated $672K trimmed.
- GatePass Capital's largest Q2 2025 buy was iShares Broad USD High Yield Corporate Bond ETF: 22,600 shares worth $848K.
- GatePass Capital added most to WisdomTree Floating Rate Treasury Fund in Q2 2025, an estimated $2.98M increase.
- GatePass Capital's biggest Q2 2025 reduction was GraniteShares ETF Trust GraniteShares 2x Long NVDA Daily ETF, cutting an estimated $672K.
- GatePass Capital fully exited INmune Bio in Q2 2025, selling an estimated $1.84M.
- GatePass Capital's ten largest holdings make up 46% of its $151M portfolio in Q2 2025.
- GatePass Capital opened 17 new positions and closed 5 in Q2 2025.
- GatePass Capital's portfolio value rose 13% quarter-over-quarter to $151M.
Based on GatePass Capital's 13F filing for Q2 2025, filed 22 Sep 2025.